Larimar Therapeutics

Larimar Therapeutics Advances Nomlabofusp Clinical Program with First Patient Dosed in Open Label Extension Study

BALA CYNWYD, PA — Clinical-stage biotechnology company Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the dosing of the first patient in an open label extension (OLE) study for its novel …

Larimar Therapeutics Advances Nomlabofusp Clinical Program with First Patient Dosed in Open Label Extension Study Read More




INOVIO Pharmaceuticals

Innovation Meets Acceleration: INOVIO Advances in Treatment for Respiratory Disease and Beyond

PLYMOUTH MEETING, PA — Biotechnology company INOVIO (NASDAQ: INO) is making considerable strides with its lead program, INO-3107, aimed at addressing Recurrent Respiratory Papillomatosis (RRP). This progress, backed by encouraging …

Innovation Meets Acceleration: INOVIO Advances in Treatment for Respiratory Disease and Beyond Read More